Stock Track | Artivion Plunges 31.11% After-Hours on Lowered 2026 Outlook Despite Q1 Beat

Stock Track05-08

Artivion's stock plummeted 31.11% in after-hours trading on Thursday, following the release of its first-quarter financial results.

The cardiac device maker reported Q1 revenue of $116.3 million, an 18% year-over-year increase that slightly beat analyst expectations. Adjusted earnings per share came in at $0.08, also surpassing estimates. However, investor sentiment turned sharply negative as the company revised its full-year 2026 guidance downward.

Artivion lowered its revenue outlook to a range of $480 million to $496 million, from a previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA guidance to $100 million to $107 million. Management indicated that U.S. revenue from the recently FDA-approved NEXUS Aortic Arch System is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161710319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 04:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161710319","market":"sg","top_or_hot":-1,"title":"Stock Track | Artivion Plunges 31.11% After-Hours on Lowered 2026 Outlook Despite Q1 Beat","media":"Stock Track","content":"<p>Artivion's stock plummeted 31.11% in after-hours trading on Thursday, following the release of its first-quarter financial results.</p><p>The cardiac device maker reported Q1 revenue of $116.3 million, an 18% year-over-year increase that slightly beat analyst expectations. Adjusted earnings per share came in at $0.08, also surpassing estimates. However, investor sentiment turned sharply negative as the company revised its full-year 2026 guidance downward.</p><p>Artivion lowered its revenue outlook to a range of $480 million to $496 million, from a previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA guidance to $100 million to $107 million. Management indicated that U.S. revenue from the recently FDA-approved NEXUS Aortic Arch System is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Artivion Plunges 31.11% After-Hours on Lowered 2026 Outlook Despite Q1 Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Artivion Plunges 31.11% After-Hours on Lowered 2026 Outlook Despite Q1 Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 04:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Artivion's stock plummeted 31.11% in after-hours trading on Thursday, following the release of its first-quarter financial results.</p><p>The cardiac device maker reported Q1 revenue of $116.3 million, an 18% year-over-year increase that slightly beat analyst expectations. Adjusted earnings per share came in at $0.08, also surpassing estimates. However, investor sentiment turned sharply negative as the company revised its full-year 2026 guidance downward.</p><p>Artivion lowered its revenue outlook to a range of $480 million to $496 million, from a previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA guidance to $100 million to $107 million. Management indicated that U.S. revenue from the recently FDA-approved NEXUS Aortic Arch System is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AORT","symbol_name":"Artivion","start_time":0,"source_url":"","article_id":"1161710319","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161710319","pubTimestamp":1778187426,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Artivion's stock plummeted 31.11% in after-hours trading on Thursday, following the release of its first-quarter financial results.The cardiac device maker reported Q1 revenue of $116.3 million, an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AORT":"Artivion"},"translate_title":"股票追踪|Artivion盘后暴跌31.11%，因2026年前景下调，尽管第一季度表现出色","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":1},"content_text":"Artivion's stock plummeted 31.11% in after-hours trading on Thursday, following the release of its first-quarter financial results.The cardiac device maker reported Q1 revenue of $116.3 million, an 18% year-over-year increase that slightly beat analyst expectations. Adjusted earnings per share came in at $0.08, also surpassing estimates. However, investor sentiment turned sharply negative as the company revised its full-year 2026 guidance downward.Artivion lowered its revenue outlook to a range of $480 million to $496 million, from a previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA guidance to $100 million to $107 million. Management indicated that U.S. revenue from the recently FDA-approved NEXUS Aortic Arch System is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161710319","isCrawlerRequest":true}